Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line

Cancer Cell International

Mohamed F ElShal²  Zoheir A Damanhouri¹  Sameer E Al-Harthi¹  Hadeel M Bayoumi¹  Abdel-Moneim M Osman¹ 

[1] Department of Pharmacology, Faculty of Medicine, King Abdul-Aziz University, Jeddah, Saudi Arabia;Depatment of Biochemistry, Faculty of Science, King Abdul-Aziz University, Jeddah, Saudi Arabia

关键词: Breast cancer cell line;    Resveratrol;    Doxorubicin;   

Others  :  797383
DOI  :  10.1186/1475-2867-12-47

 received in 2012-09-27, accepted in 2012-10-08,  发布年份 2012

【 摘 要 】

Background

Breast cancer is the most common cancer in the Arab world and it ranked first among Saudi females. Doxorubicin (DOX), an anthracycline antibiotic is one of the most effective anticancer agents used to treat breast cancer. chronic cardiotoxicity is a major limiting factor of the use of doxorubicin. Therefore, our study was designed to assess the role of a natural product resveratrol (RSVL) on sensitization of human breast cancer cells (MCF-7) to the action of DOX in an attempt to minimize doxorubicin effective dose and thereby its side effects.

Methods

Human breast cancer cell line MCF-7, was used in this study. Cytotoxic activity of DOX was determined using (sulforhodamine) SRB method. Apoptotic cells were quantified after treatment by annexin V-FITC- propidium iodide (PI) double staining using flow-cytometer. Cell cycle disturbance and doxorubicin uptake were determined after RSVL or DOX treatment.

Results

Treatment of MCF-7 cells with 15 μg/ml RSVL either simultaneously or 24 h before DOX increased the cytotoxicity of DOX, with IC50 were 0.056 and 0.035 μg/ml, respectively compared to DOX alone IC50 (0.417 μg/ml). Moreover, flow cytometric analysis of the MCF-7 cells treated simultaneously with DOX (0.5 μg/ml) and RSVL showed enhanced arrest of the cells in G₀ (80%). On the other hand, when RSVL is given 24 h before DOX although there was more increased in the cytotoxic effect of DOX against the growth of the cells, however, there was decreased in percentage arrest of cells in G₀, less inhibition of DOX-induced apoptosis and reduced DOX cellular uptake into the cells.

Conclusion

RSVL treatment increased the cytotoxic activity of DOX against the growth of human breast cancer cells when given either simultaneously or 24 h before DOX.

【 授权许可】

   
2012 Osman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Najjar H, Easson A: Age at diagnosis of breast cancer in Arab nations. Int J Surg 2010, 8(6):448-452.
• [2]Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992, 19(6):670-686.
• [3]Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32(2):302-314.
• [4]Goswami SK, Das DK: Resveratrol and chemoprevention. Cancer Lett 2009, 284(1):1-6.
• [5]Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B: Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents 2003, 3(2):77-93.
• [6]Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007, 224(3):274-283.
• [7]Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A):2783-2840.
• [8]Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112.
• [9]Van Engeland M, Nieland LJ, Ramaekerss FC, Schutte B, Reutelingsperger CP: Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31(1):1-9.
• [10]Pozarowski P, Darzynkiewicz Z: Analysis of Cell Cycle by Flow Cytometry Methods. Mol.Biol 2004, 281:301-311.
• [11]Kitagawa S, Nabekura T, Kamiyama S: Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 2004, 56(8):1001-1005.
• [12]Buzadar AS, Marcus TL, Smith TL, Blumenschein GR: Early and delayed clinical cardio toxicity of doxorubicin. Cancer 1981, 55(12):2761-2765.
• [13]Kantrowitz NE, Bristow MR: Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984, 27(3):195-200.
• [14]Meiyanto E, Hermawan A, Junedi S, Fitriasari A, Susidarti RA: Nobile tin increased cytotoxic activity Of doxorubicin on Mcf-7 cells but not on T47d cells. IJOP 2011, 3(1):129-137.
• [15]Ling YH, El-Naggar AK, Priebe W, Perez-Soler R: Cell cycle dependent cytotoxicity, G2-M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized p388 cells. Mol Pharmacol 1996, 49(5):832-841.
• [16]Ormrod D, Holm K, Goa K, Spencer C: Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 1999, 15(5):389-416.
• [17]Stacey D, Hitomi M, Chen G: Infleunce of cell cycle and oncogene activity upon topoisomerase IIa expression and drug toxicity. Mol Cell Biol 2000, 20(24):9127-9130.
• [18]Juan ME, Vinardell MP, Planas JM: The daily oral administration of highdoses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002, 132(2):257-260.
• [19]Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA, Bilir A: Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 2012, 64(5):471-479.
• [20]Gusman J, Malonne H, Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22(8):1111-1117.
• [21]Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and Induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 2001, 7(5):1466-1473.
• [22]Dörrie J, Gerauer H, Wachter Y, Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase 9 in acute lymphoblastic leukemia cells. Cancer Res 2001, 61(12):4731-4739.
• [23]Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P, Zappia V: Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998, 250(1):53-58.
• [24]Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, Greil R, Kofler R, Csordas A: Resveratrol causes arrest in the S-phase prior to Fas independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 2000, 7(9):834-842.
• [25]Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines, Clin. Cancer Res 2002, 8:893-903.
• [26]Huang C, Ma WY, Goranson A, Dong Z: Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, Lond 1999, 20(2):237-242.
• [27]Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM: The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 2002, 64(9):1375-1386.
• [28]Gupta SC, Kannappanm R, Reuter S, Kim JH, Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 2011, 1215:150-160.
• [29]Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, El-Eraky WI, El-Shemy HA: Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 2011, 44(6):591-601.
• [30]KIM HS, Kim TH: Resveratrol enhances the sensitivity of doxorubicin mediated cell proliferation, invasion, and migration in human breast cancer cell lines. 2010. http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/964.10 webcite
• [31]Yang SY, Tsai SY, Hou SC, Chao PDL: Inductive modulation on Pglycoprotein and cytochrome3A by resveratrol, a constituent of grapes. Food Chemistry 2012, 133(3):683-688.
• [32]Chaudhary P, Roninson I: Induction of multi-drug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993, 85(8):632-639.
• [33]Herzog C, Tsokos M, Bates S, Fojo A: Increased mdr-1/P Glycoproteinexpression after treatment of human colon carcinoma cells with P Glycoprotein antagonists. J Biol Chem 1993, 268(4):2946-2952.